

PTO

17 MAY 2003

10/521297

CASE TX/4-32510A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV52461579805

Express Mail Label Number

May 17, 2005

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
BRINKMANN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2003/008085

FILED: 23 JULY 2003

U.S. APPLICATION NO: 10/521,297

35 USC §371 DATE: Herewith

FOR: USE OF S1P RECEPTOR AGONISTS IN HEART DISEASES

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references which were cited in a search report (copy enclosed) in a corresponding British application are enclosed.

Some of the listed references were cited in a search report in a corresponding British application. Copies of these references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initiated PTO 1449 form(s).

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7909

  
\_\_\_\_\_  
Thomas R. Savitsky  
Attorney for Applicants  
Reg. No. 31,661

Date: *May 16, 2005*

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
TX4-32510  
APPLICATION NO.  
10/521,297  
APPLICANT  
BRINKMANN ET AL.  
FILING DATE  
Herewith

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/M.F./	AA	* 6,004,565	12/21/99	Chiba			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	* 0 627 406	12/7/04	EP			<input type="checkbox"/>	<input type="checkbox"/>
/M.F./	AN	1 002 792	5/24/00	EP			<input type="checkbox"/>	<input type="checkbox"/>
/M.F./	AO	1 201 236	5/2/02	EP			<input type="checkbox"/>	<input type="checkbox"/>
/M.F./	AP	02/076995	10/3/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
/M.F./	AQ	02/18395	3/7/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AR	* 03/020313	3/13/03	WO			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AS	* Cleland et al., "What is the Optimal Medical Management of Ischaemic Heart Failure?", British Medical Bulletin, Vol. 59, pp. 135-140 (2001).
	AT	* Kardiner, "Lysophospholipids and the Cardiovascular System", Biochimica et Biophysica Acta, Vol. 1582, No. 1-3, pp. 216-221 (2002).
	AU	* Lilioni et al., "Sphingosylphosphocholine is a Naturally Occurring Lipid Mediator in Blood Plasma. A Possible Role in Regulating Cardiac Function via Sphingolipid Receptors", Biochemical Journal, Vol. 355, No. 1, pp. 180-197 (2001).

EXAMINER

/Meghan Finn/

DATE CONSIDERED

03/11/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOROTHY NO.  
TX/4-32510  
APPLICATION NO.  
10/521,297  
APPLICANT  
BRINKMANN ET AL.  
FILING DATE  
Herewith

Group

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/M.F./	BA	* Lynch, "Lysophospholipid Receptor Nomenclature", Biochimica et Biophysica Acta, Vol. 1502, No. 1-3, pp. 70-74 (2002).
	BB	* Pyne et al., "Sphingosine 1 phosphate Signalling via the Endothelial Differentiation Gene Family of G Protein-Coupled Receptors", Pharmacology and Therapeutics, Vol. 88, pp. 115-131 (2000).
/M.F./	BC	Mazurais et al., "Cell Type-Specific Localization of Human Cardiac S1P Receptors", J. Histochem. Cytochem., Vol. 50, No. 5, pp. 661-669 (2002).
/M.F./	BD	Hwang et al., "FTY720, a New Immunosuppressant, Promotes Long-Term Graft Survival and Inhibits the Progression of Graft Coronary Artery Disease in a Murine Model of Cardiac Transplantation", Circulation, Vol. 100, No. 12, pp. 1322-1329 (1999); CAPLUS 1999:658439.
/M.F./	BE	Miyamoto et al., "Therapeutic Effects of FTY720, a New Immunosuppressive Agent, in a Murine Model of Acute Viral Myocarditis", Journal of the American College of Cardiology, Vol. 37, No. 6, pp. 1713-1718 (2001); CAPLUS 2001:382829.
	BF	
	BG	
	BH	
	BI	
	BJ	
	BK	
	BL	
	BM	
	BN	

EXAMINER

/Meghan Finn/

DATE CONSIDERED

03/11/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.